0001209191-18-059445.txt : 20181120
0001209191-18-059445.hdr.sgml : 20181120
20181120164040
ACCESSION NUMBER: 0001209191-18-059445
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20181119
FILED AS OF DATE: 20181120
DATE AS OF CHANGE: 20181120
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stankovic Srdjan R.
CENTRAL INDEX KEY: 0001432545
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50768
FILM NUMBER: 181195982
MAIL ADDRESS:
STREET 1: 35 NORTHEAST INDUSTRIAL ROAD
CITY: BRANFORD
STATE: CT
ZIP: 06405
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001070494
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 061376651
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3611 VALLEY CENTRE DRIVE
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 858-558-2871
MAIL ADDRESS:
STREET 1: 3611 VALLEY CENTRE DRIVE
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-11-19
0
0001070494
ACADIA PHARMACEUTICALS INC
ACAD
0001432545
Stankovic Srdjan R.
C/O ACADIA PHARMACEUTICALS INC.
3611 VALLEY CENTRE DRIVE, STE. 300
SAN DIEGO
CA
92130
0
1
0
0
President
Employee Stock Options (Right to Buy)
18.12
2018-11-19
4
A
0
150000
0.00
A
2028-11-18
Common Stock
150000
150000
D
Restricted Stock Units
2018-11-19
4
A
0
25000
0.00
A
Common Stock
25000
25000
D
25% of the shares subject to the Stock Option vest and become exercisable on November 19, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.
The restricted stock units vest in four equal annual installments beginning November 19, 2019.
/s/ Austin D. Kim, Attorney-in-Fact
2018-11-20
EX-24.4_817990
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby authorizes each of
Austin D. Kim, Reena Desai, Eric Miller or Martin Choy to execute for and on
behalf of the undersigned, in the undersigned's capacity as an officer of ACADIA
Pharmaceuticals Inc. (the "Company"), Forms 3, 4 and 5 and any Amendments
thereto, and cause such form(s) to be filed with the Securities and Exchange
Commission pursuant to Section 16(a) of the Securities Exchange Act of 1934,
relating to the undersigned's beneficial ownership of securities in the Company.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or substitute or
substitutes of such attorney-in-fact, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers herein granted. The
undersigned acknowledges that the each such attorney-in-fact, in serving in such
capacity at the request of the undersigned, is not assuming, nor is the Company
assuming, any of the undersigned's responsibilities to comply with Section 16 of
the Securities Exchange Act of 1934.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of, and transactions in, securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to the foregoing attorney-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed this 19th day of November 2018.
/s/ Srdjan R. Stankovic, M.D., M.S.P.H.